Obstet Gynecol Sci.  2019 Sep;62(5):335-343. 10.5468/ogs.2019.62.5.335.

Oxidative stress markers and lipid profiles of patients with polycystic ovary syndrome in a Nigerian tertiary hospital

• Enechukwu
• Onuegbu AJ
• Olisekodiaka MJ
• Eleje GU
• Ikechebelu JI
• Ugboaja JO
• Amah UK
• Okwara JE
• Igwegbe AO

• KMID: 2456829
• DOI: http://doi.org/10.5468/ogs.2019.62.5.335

Abstract

OBJECTIVE
To determine the activities of oxidative stress markers and lipid profiles of patients with polycystic ovary syndrome (PCOS) in Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria.
METHODS
This was a nested case-control study consisting of 50 PCOS patients and 50 healthy women of the same age range without any evidence of PCOS. The study measured the levels of malondialdehyde (MDA), activity of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), total antioxidant capacity (TAC); concentrations of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), as well as high-density lipoprotein cholesterol (HDL-C) using standard spectrophotometric methods. Anthropometric indices were also assessed. P-values of <0.05 were taken to be statistically significant.
RESULTS
There were significantly higher levels of MDA (P=0.002), lower activity of SOD (P<0.001), and lower TAC (P=0.001) in PCOS patients when compared with the controls. There were higher concentrations of TC (P=0.017) and LDL-C P=0.012) in PCOS patients than in controls. Significant differences were not observed between the 2 groups in terms of the activity of GSH-Px, as well as the concentrations of HDL-C and TG. The body mass index, waist circumference, and waist-hip ratio were all significantly higher in PCOS patients.
CONCLUSION
This study revealed higher levels of MDA, as well as lower activity of SOD and TAC, among PCOS patients. Furthermore, there were higher levels of TC and LDL-C among the PCOS patients. Hence, monitoring these parameters may improve the clinical management of PCOS.

Keyword

Polycystic ovary syndrome; Oxidative stress; Dyslipidaemia; Obesity; Cardiometabolic risks

MeSH Terms

Body Mass Index
Case-Control Studies
Cholesterol
Female
Glutathione Peroxidase
Hospitals, Teaching
Humans
Lipoproteins
Malondialdehyde
Nigeria
Obesity
Oxidative Stress*
Polycystic Ovary Syndrome*
Superoxide Dismutase
Tertiary Care Centers*
Triglycerides
Waist Circumference
Waist-Hip Ratio
Cholesterol
Glutathione Peroxidase
Lipoproteins
Malondialdehyde
Superoxide Dismutase
Triglycerides

Figure

• 

  Fig. 1 Flow pattern of the study.

Reference

1. Lee JY, Baw CK, Gupta S, Aziz N, Agarwal A. Role of oxidative stress in polycystic ovary syndrome. Curr Womens Health Rev. 2010; 6:96–107.

2. Karabulut AB, Cakmak M, Kiran RT, Sahin I. Oxidative stress status, metabolic profile and cardiovascular risk factors in patients with polycystic ovary syndrome. Med Sci (Turkey). 2012; 1:27–34.

3. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003; 9:505–514.

4. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81:19–25.

5. Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS. Front Horm Res. 2013; 40:51–63.

6. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol. 2008; 139:59–64.

7. Igwegbe AO, Eleje GU, Enechukwu CI. Polycystic ovary syndrome: a review of management outcomes in a low resource setting. J Womens Health Issues Care. 2013; 2:3.

8. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod. 2002; 17:2219–2227.

9. Hussein B, Alalaf S. Prevalence and characteristics of polycystic ovarian syndrome in a sample of infertile Kurdish women attending IVF infertility center in maternity teaching hospital of Erbil City. Open J Obstet Gynecol. 2013; 3:577–585.

10. Joe-kechebelu NN, Mbamara SU, Ikechebelu JI. Familial trend in polycystic ovarian syndrome: report of two cases. Ann Afr Med. 2013; 12:182–184.

11. Betteridge DJ. What is oxidative stress? Metabolism. 2000; 49:3–8.

12. Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha SR, Bitla AR. Oxidative stress in non-obese women with polycystic ovarian syndrome. J Clin Diagn Res. 2014; 8:CC01–03.

13. Yoshikawa T, Naito Y. What is oxidative stress? Japan Med Assoc J. 2002; 45:271–276.

14. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39:44–84.

15. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes. 2006; 30:400–418.

16. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012; 10:49.

17. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005; 3:28.

18. Aguilar A, Alvarez-Vijande R, Capdevila S, Alcoberro J, Alcaraz A. Antioxidant patterns (superoxide dismutase, glutathione reductase, and glutathione peroxidase) in kidneys from non-heart-beating-donors: experimental study. Transplant Proc. 2007; 39:249–252.

19. Rubio CP, Hernández-Ruiz J, Martinez-Subiela S, Tvarijonaviciute A, Ceron JJ. Spectrophotometric assays for total antioxidant capacity (TAC) in dog serum: an update. BMC Vet Res. 2016; 12:166.

20. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001; 34:407–413.

21. Wang HF, Zhong XH, Shi WY, Guo B. Study of malondialdehyde (MDA) content, superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities in chickens infected with avian infectious bronchitis virus. Afr J Biotechnol. 2011; 10:9213–9217.

22. Fisher RA. The logic of inductive inference. J R Stat Soc. 1935; 98:39–82.

23. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008 [Internet]. Geneva: World Health Organization;c2011. cited 2017 May 18. Available from: http://www.who.int/iris/handle/10665/44583.

24. Zhang D, Luo WY, Liao H, Wang CF, Sun Y. The effects of oxidative stress to PCOS. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008; 39:421–423.

25. Kuşçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009; 88:612–617.

26. Yilmaz N, Inal HA, Gorkem U, Sargin Oruc A, Yilmaz S, Turkkani A. Follicular fluid total antioxidant capacity levels in PCOS. J Obstet Gynaecol. 2016; 36:654–657.

27. Dos Santos ACS, Azevedo GD, Lemos TMAM. The influence of oxidative stress in inflammatory process and insulin resistance in obese women with polycystic ovary syndrome. Transl Biomed. 2016; 7:4.

28. Fadhil JA, Nada NA, Wasan GA. Total antioxidant capacity and homocysteine levels in obese women with polycystic ovary syndrome. Int J Pharm Pharm Res. 2017; 8:78–86.

29. Manikkumar R, Dinesh Roy D, Krishnan V, Vijayakumar T. Association of DNA damage and dyslipidemia with polycystic ovarian syndrome. J Med Allied Sci. 2013; 3:15–21.

30. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011; 95:1073–1079.e1-11.

31. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95:2038–2049.

32. Ahmed Alobaidi AH, Abrahem MK, Ahmad SS, Alsamarai AM. Dyslipidemia and oxidative stress in Iraqi women with poly cystic ovary syndroms. World J Pharm Pharm Sci. 2015; 4:39–48.

33. Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013; 56:137–142.

34. Balen A. The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol. 2004; 18:685–706.

35. Mosca L. Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol. 2007; 10:Suppl 4. 19–25.

36. ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 108: polycystic ovary syndrome. Obstet Gynecol. 2009; 114:936–949.

37. Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab. 2013; 98:4655–4663.